Back to News
Market Impact: 0.35
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Inventiva expects to report top-line results in Q4 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor for metabolic dysfunction-associated steatohepatitis (MASH). The readout is a key late-stage clinical catalyst for Inventiva, though efficacy and safety outcomes remain uncertain until results are released.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IVA0.45
More News
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- A 'weird' IPO pull, a tainted reputation and the stalled breakout moment for AI wearables
- Former L’Oréal execs set out to build a $1.2 billion beauty empire. Now all that’s left is Milk Makeup, and its sales just fell 57%
- Sports betting is increasingly the norm for Gen Z. Here’s why some financial and mental health experts are worried
- Why brands like E.l.f., Wendy's and Gap are branching out into original music
- Chick-fil-A wants to stay a family business even as it expands in the U.S. and abroad